Scope
Several complexities dictate the tumor cell response to stress. Cellular Senescence arises a primary phenotype that influences the fate of tumor cells following stress precipitated by the exposure to anticancer therapy, which is often termed “Therapy-Induced Senescence” (TIS). TIS is now being recognized as a major contributor to cancer therapy outcomes, a fundamental element of the tumor microenvironment, and a primary target for novel anticancer therapeutics. In addition to contributing to treatment resistance, facilitation of migratory and immune-evasive potential, and tumor dormancy, TIS accounts for the development of several therapy-induced adverse effects.
The Saleh lab studies the roles, mechanisms and significance of TIS in cancer treatment. We use preclinical and clinical models to understand the exact role of TIS in mediating the ultimate tumor cell date. We also focus on investigating the use of pharmacological interventions to modulate the effects mediated by the development of TIS as a consequence to anticancer therapy. The lab also focuses on studying the contribution of TIS to multiple toxicities that result from cancer treatment.
Members
Our team is comprised of experienced researchers and scientists with a diverse range of specializations. We have expertise in cancer pharmacology, cellular senescence, drug discovery, and preclinical and clinical development. Our team members have received their training from top institutions around the world and are dedicated to advancing the field of biomedical research.
Tareq Saleh MD, PhD
Principal Investigator
Associate Professor of Pharmacology and Toxicology
Arabian Gulf University
The Hashemite University
tareq@hu.edu.jo
tareqnrs@agu.edu.bh
Tel: +973 17 239 547
Sofian Al Shboul MD, PhD
Assistant Professor of Molecular and Clinical Medicine
The Hashemite University
sofian@hu.edu.jo
Tel: +962 (05) 390 3333 (5608)
Ashraf I. Khasawneh MD, PhD
Associate Professor of Virology
Clinical Microbiology Fellow
The Hashemite University
National Institutes of Health
ashrafkh@hu.edu.jo
ashraf.khasawneh@nih.gov
Tel: +962 (05) 390 3333 (5562)
Ola Abu Al Karsaneh, MD
Assistant Professor of Pathology
The Hashemite University
olaa@hu.edu.jo
Ahmad Alhesa, MSc
Research Associate
ahm8171602@ju.edu.jo
Mohammed El-Sadoni, MSc
Research Associate
mhm8191130@ju.edu.jo
Nebras Melhem, MSc
Research Associate
nebras@hu.edu.jo
Kholoud Friehat
Master Student
k.frehat@ju.edu.jo
Ongoing Projects
Investigating the Elimination of Senescent Tumor Cells by Senolytics and The Potential Interference with Their Tumor-initiating Potential.
Investigating the Elimination of HPV Infection-Induced Senescent Cells as An Approach to Decrease the Risk of Cervical Cancer.
Investigating the Connection Between Therapy-Induced Senescence and Autophagy in Tumor Cells.
Constructing 3D In Vitro Models To Study Therapy-Induced Senescence in Tumor Cells.
Investigating Cellular Senescence as A Response to Anticancer Therapy and A Contributor to Therapy Outcome in Clinical Cancers.
The Exploitation of Therapy-Induced Senescence as A Target For the Mitigation of Chemotherapy-Associated Adverse Effects.
Molecular Identification of Oncogene-Induced Senescence in Precancerous Lesions.
Investigating The Connection Between Senescence, Stemness, and Immune Response in Glioblastoma.
Selected Publications
Saleh T, Greenberg EF, Faber AC, Harada H, Gewirtz DA. A Critical Appraisal of the Utility of Targeting Therapy-induced Senescence for Cancer Treatment. Cancer Research. 2025 Mar 4. https://doi.org/10.1158/0008-5472.CAN-24-2219
Khasawneh AI, Al Shboul S, Himsawi N, Al Rousan A, Shahin NA, El-Sadoni M, Alhesa A, Abu Ghalioun A, Khawaldeh S, Shawish B, Mahfouz SA. Resolution of oncogene-induced senescence markers in HPV-infected cervical cancer tissue. BMC cancer. 2025 Jan 21;25(1):111. https://doi.org/10.1186/s12885-025-13499-0
Saleh T, Himsawi N, Al Rousan A, Alhesa A, El-Sadoni M, Khawaldeh S, Shahin NA, Ghalioun AA, Shawish B, Friehat K, Alotaibi MR. Variable Expression of Oncogene-Induced Senescence/SASP Surrogates in HPV-Associated Precancerous Cervical Tissue. Current Issues in Molecular Biology. 2024 Dec 2;46(12):13696-712. doi.org/10.3390/cimb46120818
Saleh T. Therapy-induced senescence is finally escapable, what is next? Cell Cycle. 2024 Jun 16:1-9. doi: 10.1080/15384101.2024.2364579
Elshazly AM, Shahin U, Al Shboul S, Gewirtz DA, Saleh T. A conversation with ChatGPT on contentious issues in senescence and cancer research. Mol Pharmacol. 2024 Mar 8:MOLPHARM-EMC-2024-000871. doi: 10.1124/molpharm.124.000871
Saleh, T., Naffa, R., Barakat, N.A. et al. Cisplatin Provokes Peripheral Nociception and Neuronal Features of Therapy-Induced Senescence and Calcium Dysregulation in Rats. Neurotox Res. 2024. doi.org/10.1007/s12640-024-00690-7
Abu‐Humaidan AH, Ismail MA, Ahmad FM, Al Shboul S, Barham R, Tadros JS, Alhesa A, El‐Sadoni M, Alotaibi MR, Ababneh NA, Saleh T. Therapy‐induced senescent cancer cells exhibit complement activation and increased complement regulatory protein expression. Immunology and Cell Biology. 2024. doi: 10.1111/imcb.12727
Alsalem M, Ellaithy A, Bloukh S, Haddad M, Saleh T. Targeting therapy-induced senescence as a novel strategy to combat chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2024 Jan 5;32(1):85. doi: 10.1007/s00520-023-08287-0
Al Shboul S, Boyle S, Singh A, Saleh T, Alrjoub M, Abu Al Karsaneh O, Mryyian A, Dawoud R, Gul S, Abu Baker S, Ball K, Hupp T, Brennan PM. FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma. Brain Tumor Pathol. 2023 Dec 14. doi: 10.1007/s10014-023-00473-6
Softah A, Alotaibi MR, Alhoshani AR, Saleh T, Alhazzani K, Almutairi MM, AlRowis R, Alshehri S, Albekairy NA, Harada H, Boyd R. The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells. Biomedicines. 2023 Nov;11(11):3066. doi.org/10.3390/biomedicines11113066
Saleh T, Bloukh S, Hasan M, Al Shboul S. Therapy-induced senescence as a component of tumor biology: Evidence from clinical cancer. Biochim Biophys Acta-Reviews Canceri. 2023;1878:188994. doi:10.1016/J.BBCAN.2023.188994
Al Shboul S, El-Sadoni M, Alhesa A, et al. NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy. Sci Rep. 2023;13:15903. doi:10.1038/s41598-023-42994-2
El-Sadoni M, Shboul S Al, Alhesa A, et al. A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2023;91(4):345-360. doi:10.1007/S00280-023-04523-W
DeLuca VJ, Saleh T. Insights into the role of senescence in tumor dormancy: mechanisms and applications. Cancer Metastasis Rev. 2023;42(1):19-35. doi:10.1007/S10555-023-10082-6
Shboul S Al, DeLuca VJ, Dweiri Y Al, Saleh T. Can 3D bioprinting solve the mystery of senescence in cancer therapy? Ageing Res Rev. 2022;81:101732. doi:10.1016/j.arr.2022.101732
Alotaibi M, Al-Aqil F, Alqahtani F, et al. Alleviation of cisplatin-induced neuropathic pain, neuronal apoptosis, and systemic inflammation in mice by rapamycin. Front Aging Neurosci. 2022;14. doi:10.3389/FNAGI.2022.891593
Saleh T, Gewirtz DA. Considering therapy-induced senescence as a mechanism of tumour dormancy contributing to disease recurrence. Br J Cancer. 2022;126(10):1363-1365. doi:10.1038/S41416-022-01787-6
Carpenter V, Saleh T, Min Lee S, et al. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Biochem Pharmacol. 2021;193:114765. doi:10.1016/J.BCP.2021.114765
Saleh T, Carpenter VJ. Potential Use of Senolytics for Pharmacological Targeting of Precancerous Lesions. Mol Pharmacol. September 2021:MOLPHARM-EMC-2021-000361. doi:10.1124/MOLPHARM.121.000361
Saleh T, Alhesa A, Al-Balas M, et al. Expression of therapy-induced senescence markers in breast cancer samples upon incomplete response to neoadjuvant chemotherapy. Biosci Rep. 2021;41(5):BSR20210079. doi:10.1042/bsr20210079
Saleh T, Carpenter VJ, Bloukh S, Gewirtz DA. Targeting tumor cell senescence and polyploidy as potential therapeutic strategies. Semin Cancer Biol. 2022;81:37-47. doi:10.1016/J.SEMCANCER.2020.12.010
Carpenter VJ, Patel BB, Autorino R, Smith SC, Gewirtz DA, Saleh T. Senescence and castration resistance in prostate cancer: A review of experimental evidence and clinical implications. Biochim Biophys acta Rev cancer. 2020;1874(2):188424. doi:10.1016/J.BBCAN.2020.188424
Saleh T, Carpenter V, Tyutyunyk‐Massey L, et al. Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X L ‐BAX Interaction. Mol Oncol. 2020;14(10):1-16. doi:10.1002/1878-0261.12761
Saleh T, Bloukh S, Carpenter VJ, et al. Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy. Cancers (Basel). 2020;12(4):822. doi:10.3390/cancers12040822
Saleh T, Tyutyunyk-Massey L, Gewirtz DADA. Tumor Cell Escape from Therapy-Induced Senescence as a Model of Disease Recurrence after Dormancy. Cancer Res. 2019;79(6):1044-1046. doi:10.1158/0008-5472.CAN-18-3437
Saleh T, Tyutyunyk-Massey L, Murray GFGF, et al. Tumor cell escape from therapy-induced senescence. Biochem Pharmacol. 2019;162:202-212. doi:10.1016/j.bcp.2018.12.013
Carpenter VJ, Saleh T, Gewirtz DA. Senolytics for cancer therapy: Is all that glitters really gold? Cancers (Basel). 2021;13(4):723. doi:10.3390/cancers13040723
Alotaibi M, Sharma K, Saleh T, Povirk LFLFLF, Hendrickson EAEAEA, Gewirtz DADA. Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells : Proliferative Recovery in Senescent Cells. Radiat Res. 2016;185(3):229-245. doi:10.1667/RR14202.1
Meetings
Our Collaborators
David A. Gewirtz
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Virginia, USA.
Nidaa Ababneh
Cell Therapy Center, The University of Jordan, Amman, 11942, Jordan
Mohammad Alsalem
Department of Anatomy and Histology, The University of Jordan, Amman, Jordan.
Ted Hupp
Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, Scotland.
Heyam Awad
Department of Pathology, Microbiology, and Forensic Medicine, The University of Jordan, Amman, Jordan.
Anas H. A. Abu-Humaidan
Department of Pathology, Microbiology, and Forensic Medicine, The University of Jordan, Amman, Jordan
Nisreen Abu Shahin
Department of Pathology, Microbiology, and Forensic Medicine, The University of Jordan, Amman, Jordan
Sachin Kote
International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland
Moureq R. Alotaibi
Department of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia
Moath Alrjoub
Department of Pathology and Microbiology, Jordan University of Science and Technology, Irbid, Jordan
Ahmad Altarifi
Department of Pharmacology, Jordan University of Science and Technology, Irbid, Jordan
Yazan Al Dweiri
Department of Biomedical Engineering, College of Engineering, Abu Dhabi University, Khalifa City, Abu Dhabi, UAE
